Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flebogamma 5% DIF for post-polio syndrome
NL-OMON55451Phase 2Active, not recruiting
- Sponsor
- Grifols
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of immune globulin in post-polio syndrome (PPS) (3 arms), sponsored by Grifols. Primary endpoint: Change in 2-minute walk distance. Started Feb 2016; status: active, not recruiting.
02
Drugs
immune globulin
03
Conditions
post-polio syndrome (PPS)
Beyond the preview
Go deeper on NL-OMON55451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55451.